Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection
- PMID: 25210168
- PMCID: PMC4249103
- DOI: 10.1128/JVI.02186-14
Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection
Abstract
Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.
Importance: Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Figures





Similar articles
-
Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.JCI Insight. 2017 Jan 26;2(2):e89574. doi: 10.1172/jci.insight.89574. JCI Insight. 2017. PMID: 28138558 Free PMC article.
-
HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.J Virol. 2015 Dec 9;90(5):2208-20. doi: 10.1128/JVI.02278-15. J Virol. 2015. PMID: 26656715 Free PMC article.
-
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses.Immunity. 2013 Oct 17;39(4):758-69. doi: 10.1016/j.immuni.2013.08.031. Epub 2013 Sep 12. Immunity. 2013. PMID: 24035365 Free PMC article.
-
Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Immunol Rev. 2017 Jan;275(1):62-78. doi: 10.1111/imr.12504. Immunol Rev. 2017. PMID: 28133804 Free PMC article. Review.
-
Broadly Neutralizing Antibodies against HIV: Back to Blood.Trends Mol Med. 2019 Mar;25(3):228-240. doi: 10.1016/j.molmed.2019.01.007. Epub 2019 Feb 18. Trends Mol Med. 2019. PMID: 30792120 Free PMC article. Review.
Cited by
-
HIV-1-Infected CD4+ T Cells Present MHC Class II-Restricted Epitope via Endogenous Processing.J Immunol. 2022 Sep 1;209(5):864-873. doi: 10.4049/jimmunol.2200145. Epub 2022 Aug 5. J Immunol. 2022. PMID: 36130133 Free PMC article.
-
Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses.J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):72-80. doi: 10.1097/QAI.0000000000001152. J Acquir Immune Defic Syndr. 2017. PMID: 27509243 Free PMC article.
-
Analysis of protective immune responses to seasonal influenza vaccination in HIV-infected individuals.Hum Vaccin Immunother. 2021 Jan 2;17(1):124-132. doi: 10.1080/21645515.2020.1754701. Epub 2020 May 15. Hum Vaccin Immunother. 2021. PMID: 32412824 Free PMC article.
-
Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.J Int AIDS Soc. 2016 Dec 9;19(1):21136. doi: 10.7448/IAS.19.1.21136. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27938646 Free PMC article.
-
High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults.Front Immunol. 2018 Sep 12;9:1975. doi: 10.3389/fimmu.2018.01975. eCollection 2018. Front Immunol. 2018. PMID: 30258437 Free PMC article. Clinical Trial.
References
-
- Binley J, Lybarger E, Crooks E, Seaman M, Gray E, Davis K, Decker J, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras G, Bibollet-Ruche F, Robinson J, Morris L, Shaw G, Montefiori D, Mascola J. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651–11668. 10.1128/JVI.01762-08. - DOI - PMC - PubMed
-
- Doria-Rose N, Klein R, Daniels M, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles S, Wyatt R, Korber B, Mascola J, Connors M. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631–1636. 10.1128/JVI.01482-09. - DOI - PMC - PubMed
-
- Nandi A, Lavine C, Wang P, Lipchina I, Goepfert P, Shaw G, Tomaras G, Montefiori D, Haynes B, Easterbrook P, Robinson J, Sodroski J, Yang X. 2010. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396:339–348. 10.1016/j.virol.2009.10.044. - DOI - PMC - PubMed
-
- Sather D, Armann J, Ching L, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757–769. 10.1128/JVI.02036-08. - DOI - PMC - PubMed
-
- Simek M, Rida W, Priddy F, Pung P, Carrow E, Laufer D, Lehrman J, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee D, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker L, Pitisuttithum P, Paris R, Walker L, Poignard P, Wrin T, Fast P, Burton D, Koff W. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337–7348. 10.1128/JVI.00110-09. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous